Promising drugs and treatment options for pediatric and adolescent patients with Hodgkin lymphoma.
Epstein-Barr virus
Hodgkin lymphoma
adolescent
chemotherapy
radiation
tumor target
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2022
2022
Historique:
received:
10
06
2022
accepted:
07
11
2022
entrez:
12
12
2022
pubmed:
13
12
2022
medline:
13
12
2022
Statut:
epublish
Résumé
Currently-available therapies for newly-diagnosed pediatric and adolescent patients with Hodgkin lymphoma result in >95% survival at 5 years. Long-term survivors may suffer from long-term treatment-related side effects, however, so the past 20 years have seen clinical trials for children and adolescents with HL gradually abandon the regimens used in adults in an effort to improve this situation. Narrower-field radiotherapy can reduce long-term toxicity while maintaining good tumor control. Various risk-adapted chemo-radiotherapy strategies have been used. Early assessment of tumor response with interim positron emission tomography and/or measuring metabolic tumor volume has been used both to limit RT in patients with favorable characteristics and to adopt more aggressive therapies in patients with a poor response. Most classical Hodgkin's lymphoma relapses occur within 3 years of initial treatment, while relapses occurring 5 years or more after diagnosis are rare. As the outcome for patients with relapsed/refractory classical Hodgkin lymphoma remains unsatisfactory, new drugs have been proposed for its prevention or treatment. This review summarizes the important advances made in recent years in the management of pediatric and adolescent with classical Hodgkin lymphoma, and the novel targeted treatments for relapsed and refractory classical Hodgkin lymphoma.
Identifiants
pubmed: 36506094
doi: 10.3389/fcell.2022.965803
pii: 965803
pmc: PMC9729954
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
965803Informations de copyright
Copyright © 2022 De Re, Repetto, Mussolin, Brisotto, Elia, Lopci, d’Amore, Burnelli and Mascarin.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet Haematol. 2021 Jun;8(6):e433-e445
pubmed: 34048682
Leukemia. 2022 Mar;36(3):601-612
pubmed: 35091658
Diagnostics (Basel). 2021 May 21;11(6):
pubmed: 34063765
Exp Hematol Oncol. 2018 May 11;7:12
pubmed: 29774169
Haematologica. 2018 May;103(5):840-848
pubmed: 29351986
Lancet Oncol. 2018 Sep;19(9):1229-1238
pubmed: 30122620
Tissue Antigens. 2015 Aug;86(2):98-113
pubmed: 26189878
Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225
pubmed: 23585445
Clin Cancer Res. 2021 Apr 15;27(8):2190-2199
pubmed: 33451977
J Exp Med. 1990 May 1;171(5):1393-405
pubmed: 1692078
Int J Cancer. 1993 Apr 22;54(1):53-9
pubmed: 8386709
Lancet Oncol. 2021 Feb;22(2):e57-e67
pubmed: 33539754
Leuk Lymphoma. 2018 Nov;59(11):2612-2621
pubmed: 29448858
Blood Adv. 2020 Sep 8;4(17):4069-4082
pubmed: 32870971
Drug Saf. 2019 Feb;42(2):295-314
pubmed: 30649747
Lancet Oncol. 2016 Sep;17(9):1283-94
pubmed: 27451390
Cancers (Basel). 2018 Oct 31;10(11):
pubmed: 30384446
Cancers (Basel). 2021 Jul 26;13(15):
pubmed: 34359644
Blood Adv. 2021 Oct 26;5(20):4291-4302
pubmed: 34610100
Br J Haematol. 2015 Jun;169(5):689-93
pubmed: 25818067
Immunity. 2022 May 10;55(5):912-924.e8
pubmed: 35413245
Cells. 2021 May 10;10(5):
pubmed: 34068762
Clin Transl Oncol. 2020 May;22(5):782-785
pubmed: 31359339
Blood Adv. 2022 Jan 25;6(2):473-485
pubmed: 34495306
Ann Oncol. 2003 Dec;14(12):1762-7
pubmed: 14630682
JCI Insight. 2016 Nov 17;1(19):e89631
pubmed: 27882350
J Clin Invest. 2017 Sep 1;127(9):3462-3471
pubmed: 28805662
Lancet Haematol. 2020 Sep;7(9):e660-e670
pubmed: 32853585
Blood Adv. 2021 Apr 13;5(7):1991-2002
pubmed: 33843986
Clin Cancer Res. 2017 Mar 1;23(5):1156-1166
pubmed: 27582488
J Clin Invest. 2018 Jul 2;128(7):2996-3007
pubmed: 29889102
Cancers (Basel). 2019 Jul 04;11(7):
pubmed: 31277480
Cancers (Basel). 2021 Oct 31;13(21):
pubmed: 34771650
Lancet Oncol. 2022 Jan;23(1):125-137
pubmed: 34895479
N Engl J Med. 2018 Jan 25;378(4):331-344
pubmed: 29224502
Pediatr Blood Cancer. 2022 Mar;69(3):e29390
pubmed: 35077016
Proc Natl Acad Sci U S A. 2009 Sep 1;106(35):14920-5
pubmed: 19706467
Lancet Oncol. 2020 Apr;21(4):541-550
pubmed: 32192573
Oncoimmunology. 2020 Jun 17;9(1):1781334
pubmed: 32934884
Genes Chromosomes Cancer. 2015 Oct;54(10):638-45
pubmed: 26194173
Blood. 2018 May 31;131(22):2454-2465
pubmed: 29650799
Nat Genet. 2006 Sep;38(9):1071-6
pubmed: 16892059
Blood. 2016 Nov 24;128(21):2489-2496
pubmed: 27574190
Lancet. 2018 Dec 23;390(10114):2790-2802
pubmed: 29061295
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):238-250
pubmed: 30291373
Recent Pat Anticancer Drug Discov. 2021;16(3):312-332
pubmed: 33563158
Leuk Res. 2020 Sep;96:106408
pubmed: 32659407
J Clin Oncol. 2010 Aug 10;28(23):3680-6
pubmed: 20625128
Proc Natl Acad Sci U S A. 2015 Oct 20;112(42):13045-50
pubmed: 26438866
J Pathol. 2014 Mar;232(4):405-14
pubmed: 24659185
Blood. 2009 Jun 4;113(23):5920-6
pubmed: 19188663
J Clin Oncol. 2007 Jul 20;25(21):3101-8
pubmed: 17536082
Proc Natl Acad Sci U S A. 2013 Dec 17;110(51):20729-34
pubmed: 24302766
MAbs. 2019 Feb/Mar;11(2):219-238
pubmed: 30516432
Blood. 2001 Feb 1;97(3):616-23
pubmed: 11157476
Front Immunol. 2018 Jun 18;9:1358
pubmed: 29967610
EMBO J. 2002 Aug 1;21(15):4104-13
pubmed: 12145210
Blood. 1995 Aug 15;86(4):1464-8
pubmed: 7632954
Int J Mol Sci. 2021 May 17;22(10):
pubmed: 34067904
Front Oncol. 2021 Dec 01;11:785635
pubmed: 34926302
Blood. 2011 Mar 3;117(9):2596-603
pubmed: 21079154
Blood. 1995 Aug 15;86(4):1493-501
pubmed: 7632957
Leuk Lymphoma. 2019 Jun;60(6):1429-1437
pubmed: 30668190
Nat Immunol. 2018 Dec;19(12):1415-1426
pubmed: 30349037
Blood. 2009 Sep 3;114(10):2051-9
pubmed: 19584400
Asian Pac J Cancer Prev. 2018 Dec 25;19(12):3463-3466
pubmed: 30583670
Curr Mol Med. 2011 Apr;11(3):236-45
pubmed: 21375490
Lancet Haematol. 2018 Oct;5(10):e450-e461
pubmed: 30290902
Int J Cancer. 1995 Nov 27;63(5):652-9
pubmed: 7591281
Pediatr Blood Cancer. 2018 Dec;65(12):e27375
pubmed: 30277639
Lancet Oncol. 2021 Apr;22(4):512-524
pubmed: 33721562
Haematologica. 2007 Jan;92(1):35-41
pubmed: 17229633
Nat Rev Dis Primers. 2020 Jul 23;6(1):61
pubmed: 32703953
World J Clin Cases. 2021 Jul 26;9(21):6041-6048
pubmed: 34368325
Blood. 2006 Oct 1;108(7):2280-9
pubmed: 16757686
J Clin Oncol. 2016 Sep 20;34(27):3293-9
pubmed: 27382096
Hemasphere. 2020 Jan 10;4(1):e329
pubmed: 32072145
Cancers (Basel). 2021 Dec 07;13(24):
pubmed: 34944778
Blood. 2018 May 31;131(22):2413-2425
pubmed: 29449275
Cancer Cell. 2010 Dec 14;18(6):590-605
pubmed: 21156283
J Clin Oncol. 2014 Mar 10;32(8):798-808
pubmed: 24344220
J Hematol Oncol. 2016 Nov 30;9(1):132
pubmed: 27899158
Blood. 2016 May 19;127(20):2375-90
pubmed: 26980727
Br J Haematol. 2022 Jun;197(5):580-589
pubmed: 35301709
Lancet Oncol. 2018 Feb;19(2):257-266
pubmed: 29276022
Cancer Manag Res. 2018 Jun 13;10:1517-1526
pubmed: 29942153
Cell Oncol (Dordr). 2015 Dec;38(6):453-62
pubmed: 26350502
Blood Adv. 2019 Dec 10;3(23):4065-4080
pubmed: 31816062
Blood. 2018 Jun 7;131(23):2552-2567
pubmed: 29685921
Infect Agent Cancer. 2020 Jun 23;15:42
pubmed: 32582365
J Clin Oncol. 2005 Sep 1;23(25):6181-9
pubmed: 16135485
Oncogene. 2004 Mar 25;23(13):2275-86
pubmed: 14755244
Ann Oncol. 2017 May 01;28(5):1057-1063
pubmed: 28327905
Clin Cancer Res. 2021 May 15;27(10):2782-2791
pubmed: 33674274
Viruses. 2020 Dec 01;12(12):
pubmed: 33271926
Cancer Imaging. 2020 Jan 03;20(1):2
pubmed: 31900236
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):257-266.e3
pubmed: 33277223
J Pers Med. 2022 Feb 01;12(2):
pubmed: 35207685
Mediterr J Hematol Infect Dis. 2009 Nov 24;1(2):e2009013
pubmed: 21416003
Blood. 2015 Feb 12;125(7):1061-72
pubmed: 25488972
Br J Haematol. 2019 Dec;187(5):573-587
pubmed: 31566730
Front Oncol. 2021 Jan 08;10:611690
pubmed: 33489922
Lancet Oncol. 2020 Jan;21(1):121-133
pubmed: 31812554
Haematologica. 2022 Jan 01;107(1):287-291
pubmed: 34498447
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32345627
Clin Cancer Res. 2020 Nov 1;26(21):5579-5587
pubmed: 33055173
J Clin Oncol. 2013 Apr 20;31(12):1562-8
pubmed: 23509321
J Clin Oncol. 2018 Apr 1;36(10):942-950
pubmed: 29394125
Biosensors (Basel). 2022 Jan 04;12(1):
pubmed: 35049651
J Immunol. 2002 Nov 15;169(10):5392-5
pubmed: 12421911
Cancers (Basel). 2020 Jun 18;12(6):
pubmed: 32570974
J Clin Oncol. 2016 Aug 10;34(23):2690-7
pubmed: 27069084
Lancet Oncol. 2014 Oct;15(11):1181-2
pubmed: 25239574
J Clin Oncol. 2019 Jun 10;37(17):1479-1489
pubmed: 31039052
Blood. 2020 Nov 19;136(21):2437-2441
pubmed: 32589698
Ann Oncol. 2007 Jun;18(6):1071-9
pubmed: 17426059
Leukemia. 2020 Jan;34(1):151-166
pubmed: 31431735
Cancer Discov. 2017 Oct;7(10):1154-1167
pubmed: 28576927
Nat Rev Cancer. 2009 Jan;9(1):15-27
pubmed: 19078975
J Clin Oncol. 2020 Nov 10;38(32):3794-3804
pubmed: 32701411
Cell. 2019 Jan 10;176(1-2):334-347.e12
pubmed: 30580966
Oncoimmunology. 2018 Jan 19;7(5):e1421889
pubmed: 29721369
Haematologica. 2016 Sep;101(9):1094-101
pubmed: 27479820
Blood. 2019 Dec 5;134(23):2059-2069
pubmed: 31697809
Pediatr Blood Cancer. 2012 Dec 15;59(7):1259-65
pubmed: 22911615